8-K: SI-BONE Q3 Revenue Jumps 21%, Raises 2025 Guidance

SI-BONE, Inc. reported strong third-quarter 2025 financial results with significant revenue growth and improved profitability, leading to an upward revision of its full-year 2025 guidance.

Summary

• Worldwide revenue increased 20.6% to $48.7 million in Q3 2025, up from $40.3 million in Q3 2024.
• U.S. revenue grew 21.2% to $46.4 million, driven by strong underlying procedure demand.
• Gross margin improved by 75 basis points to 79.8% in Q3 2025.
• Net loss improved by 30.6% to $4.6 million, or $0.11 per diluted share, compared to a $6.6 million loss ($0.16 per share) in Q3 2024.
• Adjusted EBITDA turned positive at $2.3 million in Q3 2025, up from a $0.2 million loss in Q3 2024.
• Generated $2.3 million in positive cash from operating activities during the quarter.
• Cash and equivalents stood at $145.7 million as of September 30, 2025.
• The company raised its full-year 2025 worldwide revenue guidance to $198 million to $200 million, implying 18% to 20% year-over-year growth.
• Full-year 2025 gross margin guidance was also raised to approximately 79.5%.
• Daniel Wolf resigned from the Board of Directors, and Thomas A. West was appointed to the Audit Committee.
• A consulting agreement was entered into with Mr. Wolf for 12 months, including accelerated vesting of 8,675 restricted stock units.

Sentiment

Score: 8

Explanation: The company delivered strong Q3 results with significant revenue growth, improved profitability metrics (positive adjusted EBITDA and operating cash flow), and raised its full-year guidance for both revenue and gross margin. Operational highlights like increased physician adoption and NTAP approval further bolster a positive outlook, despite continued net losses and increased operating expenses.

Positives

• Worldwide revenue grew 20.6% to $48.7 million in Q3 2025, demonstrating robust demand.
• U.S. revenue increased 21.2% to $46.4 million, driven by strong procedure demand.
• Gross margin improved by 75 basis points to 79.8%, indicating operational efficiency.
• Net loss significantly improved by 30.6% to $4.6 million.
• Adjusted EBITDA turned positive at $2.3 million, a substantial improvement from a $0.2 million loss in the prior year.
• Generated positive cash from operating activities of $2.3 million, highlighting financial health.
• Increased active U.S. physicians by 27% to 1,530, expanding market reach.
• Trailing 12-month average revenue per territory increased by 16% to $2.1 million.
• New Technology Add-on Payment (NTAP) of over $4,100 for iFuse TORQ TNT procedures, effective October 1, 2025, enhances reimbursement.
• Raised full-year 2025 worldwide revenue guidance to $198 million $200 million (18-20% growth), up from $195 million $198 million (17-18% growth).
• Raised full-year 2025 gross margin guidance to ~79.5% from 78.5% to 79.0%.

Negatives

• Operating expenses increased 11.9% to $44.2 million, primarily due to general commercial activity, new product rollout, and elevated general and administrative spend.
• The company still reported a net loss of $4.6 million, despite significant improvement.

Risks

• Ability to introduce and commercialize new products and indications.
• Ability to maintain favorable reimbursement for procedures using its products.
• Impact of any future economic weakness or deterioration in economic conditions (e.g., tariffs) on patient desire to undergo elective procedures.
• Potential impact of a government shutdown on the ability to introduce and commercialize new products.
• Ability to manage risks to its supply chain.
• Future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment.
• Pace of the re-normalization of the healthcare operating environment, including patient and physician willingness to undergo and perform procedures.

Future Outlook

SI-BONE expects continued revenue and procedure growth, with full-year 2025 worldwide revenue now projected to be between $198 million and $200 million, representing 18% to 20% year-over-year growth. The company also anticipates a full-year 2025 gross margin of approximately 79.5% and positive adjusted EBITDA, indicating a strong outlook for sustained profitable growth and self-funding innovation.

Management Comments

• "The robust procedure volume growth across all modalities and record increase in the number of physicians in the third quarter underscore the demand momentum for our differentiated platform." Laura Francis, CEO.
• "In addition to sustained topline growth, the continued expansion of our profitability and positive operating cash flow in the quarter demonstrate the strength and scalability of our asset-light business model." Laura Francis, CEO.
• "Looking beyond 2025, we are well-positioned to self-fund innovation, advance our deep pipeline of novel technologies that address unmet needs for our existing call points, and consistently deliver industry-leading profitable growth." Laura Francis, CEO.

Industry Context

SI-BONE operates in the medical device sector, specifically focusing on sacropelvic disorders and minimally invasive SI joint surgery. The strong revenue growth, increased physician adoption, and positive adjusted EBITDA suggest the company is successfully expanding its market share and product penetration within this specialized segment. The introduction of new technologies like iFuse TORQ and the associated NTAP reimbursement indicate a focus on innovation and favorable market conditions for advanced surgical solutions, aligning with broader trends in healthcare towards less invasive and more effective treatments.

Comparison to Industry Standards

• The 20.6% worldwide revenue growth and 21.2% U.S. revenue growth for Q3 2025 are strong indicators of market penetration and demand, potentially outpacing many general medical device companies. For example, larger, more diversified medical device companies might see single-digit growth, while specialized, innovative players like SI-BONE can achieve higher rates, similar to emerging growth companies in high-demand niches.
• The gross margin of 79.8% is exceptionally high, often seen in specialized medical device or software companies with strong intellectual property and pricing power, significantly above the average for manufacturing-heavy industries or even broader medical device sectors which might range from 50-70%.
• Achieving positive adjusted EBITDA of $2.3 million and positive cash from operating activities of $2.3 million, while still being a relatively smaller, growing company, demonstrates a strong path to profitability and financial discipline, which is a positive signal compared to many high-growth but unprofitable medical technology startups.
• The 27% growth in active U.S. physicians and 16% increase in average revenue per territory suggest effective sales and marketing strategies and strong physician adoption, which are critical metrics for medical device companies.

Management Changes

Corporate Governance

Related Party Transactions

• A consulting agreement was entered into with Daniel Wolf (through an entity wholly owned by him) for 12 months, providing consulting services for marketing, strategy, business development, and other corporate matters.
• The agreement includes acceleration of vesting for 8,675 restricted stock units granted to Mr. Wolf on June 5, 2025, making them fully vested as of November 6, 2025.
• Cash compensation will be at an hourly rate set forth in accepted statements of work.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, and a clear path to profitability, potentially leading to increased share value. The consulting agreement with a former director could be viewed as a way to retain expertise.
• Employees: Continued growth and innovation suggest job stability and potential for expansion.
• Customers (Physicians/Patients): Increased physician adoption and new technology (iFuse TORQ TNT with NTAP) indicate improved access to and effectiveness of treatments for sacropelvic disorders.
• Creditors: Positive cash flow from operations and a strong cash position ($145.7 million) enhance the company's financial stability and ability to meet obligations.
• Suppliers: Increased demand and new product rollouts could lead to increased business for suppliers.

Next Steps

• SI-BONE will host a conference call on November 10, 2025, to discuss the third quarter 2025 financial results.
• The full text of the Consulting Agreement with Daniel Wolf will be filed as an exhibit to the company's quarterly report on Form 10-Q for the quarter ended September 30, 2025.
• Continue to self-fund innovation and advance the pipeline of novel technologies.
• Consistently deliver industry-leading profitable growth.

Key Dates

Recommendation

The company demonstrated exceptional performance in Q3 2025, significantly exceeding prior expectations with robust revenue growth, a substantial improvement in gross margin, and a shift to positive adjusted EBITDA and operating cash flow. The upward revision of full-year 2025 guidance for both revenue and gross margin signals strong underlying business momentum and management confidence. Operational achievements, including a 27% increase in active U.S. physicians and favorable reimbursement for new technology (NTAP), underscore market leadership and future growth potential. While still reporting a net loss, the trajectory towards profitability is clear and accelerating. These factors, combined with a scalable asset-light business model and a commitment to innovation, position SI-BONE as a compelling investment opportunity.

Keywords

SI-BONE, SIBN, Q3 2025 Earnings, Financial Results, Revenue Growth, Adjusted EBITDA, Medical Device, Sacropelvic Disorders, iFuse TORQ, NTAP, Guidance Raise, Minimally Invasive Surgery, Corporate Governance